Webinar Two
Release Date: July 1, 2020, Expiration Date: June 30, 2022
Learning Objectives:
- Participants will be able to describe immune checkpoints.
- Participants will be able to understand how checkpoints are leverages by cancer.
- Participants will be able to describe therapies that target immune checkpoints.
Target Audience:
This lecture is attended for primary care physicians, specialty physicians, physician assistants and nurses.
Accreditation:
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit:
The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Planning Committee Disclosure:
Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/.
Faculty Disclosure:
Dr. Rahman has disclosed that she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.
Bibliographic Sources:
DOI: 10.1200/jco.2012.30.15_suppl.7509 Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012) 7509-7509.
Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377–3383.
Back to CME Series Main Page